253 related articles for article (PubMed ID: 26123663)
21. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
Slack A; Chen Z; Tonelli R; Pule M; Hunt L; Pession A; Shohet JM
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):731-6. PubMed ID: 15644444
[TBL] [Abstract][Full Text] [Related]
22. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
[TBL] [Abstract][Full Text] [Related]
23. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.
Gupta A; Williams BR; Hanash SM; Rawwas J
Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187
[TBL] [Abstract][Full Text] [Related]
24. A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.
Schnepp RW; Khurana P; Attiyeh EF; Raman P; Chodosh SE; Oldridge DA; Gagliardi ME; Conkrite KL; Asgharzadeh S; Seeger RC; Madison BB; Rustgi AK; Maris JM; Diskin SJ
Cancer Cell; 2015 Nov; 28(5):599-609. PubMed ID: 26481147
[TBL] [Abstract][Full Text] [Related]
25. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.
Helland Å; Anglesio MS; George J; Cowin PA; Johnstone CN; House CM; Sheppard KE; Etemadmoghadam D; Melnyk N; Rustgi AK; Phillips WA; Johnsen H; Holm R; Kristensen GB; Birrer MJ; ; Pearson RB; Børresen-Dale AL; Huntsman DG; deFazio A; Creighton CJ; Smyth GK; Bowtell DD
PLoS One; 2011 Apr; 6(4):e18064. PubMed ID: 21533284
[TBL] [Abstract][Full Text] [Related]
26. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors.
Mestdagh P; Fredlund E; Pattyn F; Schulte JH; Muth D; Vermeulen J; Kumps C; Schlierf S; De Preter K; Van Roy N; Noguera R; Laureys G; Schramm A; Eggert A; Westermann F; Speleman F; Vandesompele J
Oncogene; 2010 Mar; 29(9):1394-404. PubMed ID: 19946337
[TBL] [Abstract][Full Text] [Related]
27. LIN28B alters ribosomal dynamics to promote metastasis in MYCN-driven malignancy.
Missios P; da Rocha EL; Pearson DS; Philipp J; Aleman MM; Pirouz M; Farache D; Franses JW; Kubaczka C; Tsanov KM; Jha DK; Pepe-Mooney B; Powers JT; Gregory RI; Lee AS; Dominguez D; Ting DT; Daley GQ
J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34779407
[TBL] [Abstract][Full Text] [Related]
28. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
[TBL] [Abstract][Full Text] [Related]
29. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
[TBL] [Abstract][Full Text] [Related]
30. Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma.
Duffy DJ; Krstic A; Halasz M; Schwarzl T; Fey D; Iljin K; Mehta JP; Killick K; Whilde J; Turriziani B; Haapa-Paananen S; Fey V; Fischer M; Westermann F; Henrich KO; Bannert S; Higgins DG; Kolch W
Oncotarget; 2015 Dec; 6(41):43182-201. PubMed ID: 26673823
[TBL] [Abstract][Full Text] [Related]
31. Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients.
Ribeiro D; Klarqvist MDR; Westermark UK; Oliynyk G; Dzieran J; Kock A; Savatier Banares C; Hertwig F; Johnsen JI; Fischer M; Kogner P; Lovén J; Arsenian Henriksson M
Cell Rep; 2016 Jul; 16(4):979-993. PubMed ID: 27396325
[TBL] [Abstract][Full Text] [Related]
32. Keratoepithelin reverts the suppression of tissue factor pathway inhibitor 2 by MYCN in human neuroblastoma: a mechanism to inhibit invasion.
Becker J; Volland S; Noskova I; Schramm A; Schweigerer LL; Wilting J
Int J Oncol; 2008 Jan; 32(1):235-40. PubMed ID: 18097563
[TBL] [Abstract][Full Text] [Related]
33. miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.
Terrile M; Bryan K; Vaughan L; Hallsworth A; Webber H; Chesler L; Stallings RL
PLoS One; 2011; 6(12):e28356. PubMed ID: 22164278
[TBL] [Abstract][Full Text] [Related]
34. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis.
Chen Y; Stallings RL
Cancer Res; 2007 Feb; 67(3):976-83. PubMed ID: 17283129
[TBL] [Abstract][Full Text] [Related]
35. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
36. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
37. MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma.
Manohar CF; Bray JA; Salwen HR; Madafiglio J; Cheng A; Flemming C; Marshall GM; Norris MD; Haber M; Cohn SL
Oncogene; 2004 Jan; 23(3):753-62. PubMed ID: 14737110
[TBL] [Abstract][Full Text] [Related]
38. MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formation.
Beckers A; Van Peer G; Carter DR; Mets E; Althoff K; Cheung BB; Schulte JH; Mestdagh P; Vandesompele J; Marshall GM; De Preter K; Speleman F
Oncotarget; 2015 Mar; 6(7):5204-16. PubMed ID: 25294817
[TBL] [Abstract][Full Text] [Related]
39. Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis.
Ramaiah MJ; Pushpavalli SN; Lavanya A; Bhadra K; Haritha V; Patel N; Tamboli JR; Kamal A; Bhadra U; Pal-Bhadra M
Bioorg Med Chem Lett; 2013 Oct; 23(20):5699-706. PubMed ID: 23992861
[TBL] [Abstract][Full Text] [Related]
40. The MYCN oncogene and differentiation in neuroblastoma.
Westermark UK; Wilhelm M; Frenzel A; Henriksson MA
Semin Cancer Biol; 2011 Oct; 21(4):256-66. PubMed ID: 21849159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
